260 related articles for article (PubMed ID: 35582578)
1. Tailored therapy in patients treated with fluoropyrimidines: focus on the role of dihydropyrimidine dehydrogenase.
Merloni F; Ranallo N; Scortichini L; Giampieri R; Berardi R
Cancer Drug Resist; 2019; 2(3):787-802. PubMed ID: 35582578
[TBL] [Abstract][Full Text] [Related]
2. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.
Henricks LM; Opdam FL; Beijnen JH; Cats A; Schellens JHM
Ann Oncol; 2017 Dec; 28(12):2915-2922. PubMed ID: 29045513
[TBL] [Abstract][Full Text] [Related]
3. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
4. Clinical implications of dihydropyrimidine dehydrogenase (DPD) activity in 5-FU-based chemotherapy: mutations in the DPD gene, and DPD inhibitory fluoropyrimidines.
Omura K
Int J Clin Oncol; 2003 Jun; 8(3):132-8. PubMed ID: 12851836
[TBL] [Abstract][Full Text] [Related]
5. Pharmacogenetics and Metabolism from Science to Implementation in Clinical Practice: The Example of Dihydropyrimidine Dehydrogenase.
Del Re M; Restante G; Di Paolo A; Crucitta S; Rofi E; Danesi R
Curr Pharm Des; 2017; 23(14):2028-2034. PubMed ID: 28128059
[TBL] [Abstract][Full Text] [Related]
6. A Novel
Tong CC; Lam CW; Lam KO; Lee VHF; Luk MY
Front Oncol; 2018; 8():279. PubMed ID: 30087856
[No Abstract] [Full Text] [Related]
7. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
Del Re M; Di Paolo A; van Schaik RH; Bocci G; Simi P; Falcone A; Danesi R
EPMA J; 2010 Sep; 1(3):495-502. PubMed ID: 23199091
[TBL] [Abstract][Full Text] [Related]
8. Improving safety of fluoropyrimidine chemotherapy by individualizing treatment based on dihydropyrimidine dehydrogenase activity - Ready for clinical practice?
Meulendijks D; Cats A; Beijnen JH; Schellens JH
Cancer Treat Rev; 2016 Nov; 50():23-34. PubMed ID: 27589829
[TBL] [Abstract][Full Text] [Related]
9. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
10. Near Miss or Standard of Care?
Winquist LE; Sanatani M; Kim RB; Winquist E
Curr Oncol; 2020 Dec; 28(1):94-97. PubMed ID: 33704179
[TBL] [Abstract][Full Text] [Related]
11. Fluoropyrimidine Toxicity: the Hidden Secrets of DPYD.
Manolopoulos VG; Ragia G
Curr Drug Metab; 2024 Mar; ():. PubMed ID: 38504562
[TBL] [Abstract][Full Text] [Related]
12. Clinical Relevance of Novel Polymorphisms in the Dihydropyrimidine Dehydrogenase (
Soria-Chacartegui P; Villapalos-García G; López-Fernández LA; Navares-Gómez M; Mejía-Abril G; Abad-Santos F; Zubiaur P
Pharmaceutics; 2021 Nov; 13(12):. PubMed ID: 34959317
[TBL] [Abstract][Full Text] [Related]
13. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.
Lunenburg CATC; Henricks LM; Guchelaar HJ; Swen JJ; Deenen MJ; Schellens JHM; Gelderblom H
Eur J Cancer; 2016 Feb; 54():40-48. PubMed ID: 26716401
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of 5-fluorouracil pharmacokinetics in cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling strategy.
van Kuilenburg AB; Häusler P; Schalhorn A; Tanck MW; Proost JH; Terborg C; Behnke D; Schwabe W; Jabschinsky K; Maring JG
Clin Pharmacokinet; 2012 Mar; 51(3):163-74. PubMed ID: 22339448
[TBL] [Abstract][Full Text] [Related]
15. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
16. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics.
Mattison LK; Soong R; Diasio RB
Pharmacogenomics; 2002 Jul; 3(4):485-92. PubMed ID: 12164772
[TBL] [Abstract][Full Text] [Related]
17. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
18. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
